Related Experiment Video

Updated: Jun 24, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Ligand-based targeted therapy for cancer tissue

Manasi Das1, Chandana Mohanty, Sanjeeb K Sahoo

  • 1Laboratory for Nanomedicine, Institute of Life Sciences, Nalco Square, Chandrasekharpur, Bhubaneswar, Orissa, India.

Expert Opinion on Drug Delivery
|March 31, 2009
PubMed
Abstract

Insights

Targeted cancer therapy using nanocarrier conjugates with specific ligands enhances drug delivery to tumors. This approach improves treatment efficacy and reduces side effects, offering better patient quality of life.

Area of Science:

  • Oncology
  • Nanotechnology
  • Pharmacology

Background:

  • Cancer drug delivery faces challenges including poor tumor accessibility, high dosage requirements, severe side effects, and drug resistance.
  • Current strategies aim to overcome these limitations through advanced drug delivery systems.

Purpose of the Study:

  • To review the use of nanocarrier conjugates with targeting ligands for anticancer drug delivery.
  • To discuss the current advancements and challenges in nanocarrier-mediated targeted cancer therapy.

Main Methods:

  • Literature review of nanocarrier systems conjugated with targeting moieties.
  • Analysis of drug delivery and targeting strategies in cancer therapy.

Main Results:

  • Nanocarrier conjugates with targeting ligands show promise for improved drug delivery to tumor tissues.
  • Targeted delivery enhances therapeutic efficacy and minimizes off-target toxicity.

Conclusions:

  • Targeting ligands are crucial for effective cancer cell targeting and improving therapeutic outcomes.
  • Ligand-targeted therapy offers a path to enhanced efficacy, reduced side effects, and better patient quality of life in cancer treatment.

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.